A detailed history of Amalgamated Bank transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Amalgamated Bank holds 398,422 shares of BMY stock, worth $23.1 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
398,422
Previous 409,901 2.8%
Holding current value
$23.1 Million
Previous $17 Million 21.09%
% of portfolio
0.17%
Previous 0.14%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$39.66 - $51.75 $455,257 - $594,038
-11,479 Reduced 2.8%
398,422 $20.6 Million
Q2 2024

Aug 12, 2024

SELL
$40.25 - $52.99 $494,350 - $650,823
-12,282 Reduced 2.91%
409,901 $17 Million
Q1 2024

Apr 23, 2024

SELL
$47.98 - $54.4 $3.46 Million - $3.92 Million
-72,138 Reduced 14.59%
422,183 $22.9 Million
Q4 2023

Feb 06, 2024

SELL
$48.48 - $57.85 $1.75 Million - $2.09 Million
-36,084 Reduced 6.8%
494,321 $25.4 Million
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $661,682 - $739,863
-11,430 Reduced 2.11%
530,405 $30.8 Million
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $3.42 Million - $3.8 Million
-53,678 Reduced 9.01%
541,835 $34.7 Million
Q1 2023

May 02, 2023

BUY
$65.71 - $74.53 $2.45 Million - $2.78 Million
37,264 Added 6.68%
595,513 $41.3 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $1.29 Million - $1.53 Million
-18,861 Reduced 3.27%
558,249 $40.2 Million
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $4,342 - $2.57 Million
33,400 Added 6.14%
577,110 $41 Million
Q2 2022

Aug 15, 2022

SELL
$72.62 - $79.98 $2.5 Million - $2.75 Million
-34,359 Reduced 5.94%
543,710 $41.9 Million
Q1 2022

Jun 30, 2022

SELL
$61.48 - $73.72 $2.95 Million - $3.54 Million
-47,972 Reduced 7.66%
578,069 $42.2 Million
Q4 2021

Feb 15, 2022

BUY
$53.63 - $62.52 $1.22 Million - $1.42 Million
22,744 Added 3.77%
626,041 $39 Million
Q3 2021

Oct 29, 2021

SELL
$59.17 - $69.31 $1.49 Million - $1.74 Million
-25,101 Reduced 3.99%
603,297 $35.7 Million
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $30.9 Million - $33.7 Million
499,210 Added 386.42%
628,398 $42 Million
Q1 2021

May 13, 2021

SELL
$59.34 - $66.74 $325,598 - $366,202
-5,487 Reduced 4.07%
129,188 $8.16 Million
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $23,731 - $26,891
-411 Reduced 0.3%
134,675 $8.35 Million
Q3 2020

Oct 30, 2020

SELL
$57.43 - $63.64 $196,180 - $217,394
-3,416 Reduced 2.47%
135,086 $8.14 Million
Q2 2020

Aug 10, 2020

SELL
$54.82 - $64.09 $12.8 Million - $15 Million
-233,726 Reduced 62.79%
138,502 $8.14 Million
Q1 2020

May 13, 2020

SELL
$46.4 - $67.43 $587,145 - $853,259
-12,654 Reduced 3.29%
372,228 $20.7 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $6.74 Million - $8.79 Million
136,917 Added 55.22%
384,882 $24.7 Million
Q3 2019

Nov 13, 2019

BUY
$42.77 - $50.71 $866,691 - $1.03 Million
20,264 Added 8.9%
247,965 $12.6 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $22,756 - $25,163
-510 Reduced 0.22%
227,701 $10.3 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $248,791 - $296,653
5,514 Added 2.48%
228,211 $10.9 Million
Q4 2018

Feb 15, 2019

SELL
$48.76 - $63.23 $253,405 - $328,606
-5,197 Reduced 2.28%
222,697 $11.6 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $360,445 - $406,554
-6,531 Reduced 2.79%
227,894 $14.1 Million
Q2 2018

Jul 18, 2018

BUY
$50.53 - $62.98 $586,249 - $730,693
11,602 Added 5.21%
234,425 $13 Million
Q1 2018

May 22, 2018

BUY
$59.92 - $68.98 $618,314 - $711,804
10,319 Added 4.86%
222,823 $14.1 Million
Q4 2017

Feb 13, 2018

BUY
$59.94 - $65.35 $1.12 Million - $1.22 Million
18,698 Added 9.65%
212,504 $13 Million
Q3 2017

Nov 09, 2017

BUY
$55.23 - $63.74 $10.7 Million - $12.4 Million
193,806
193,806 $12.4 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.